January 19, 2022 7:30am

So, stay “pat” or consider buying a just a few past decliners

Pre-open indications: 3 BUYs and 2 SELL

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Only the facts …

Dow futures are UP +0.24% (+84 points), S&P futures are UP +0.31% (+14 points) and NASDAQ futures are UP +0.41% (+63 points)

 

Dow futures inch higher after a sell-off early Wednesday even though government bond yields are slightly higher,

European stocks also inched higher shrugging off concerns about rising bond yields,

Asia-Pacific markets fell following an overnight sell-off although Hong Kong bucked the trend

 

Henry’omics:

Yesterday, Tuesday the Nasdaq closed below its 200-day moving average for the first time since April 2020, and undercut the Jan. 10 intraday lows with the Russell 2000 breaking below recent lows amid spiking bond yields with a deeper dive by the cell and gene therapy sector.

 

Economic Data Docket: The average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances ($647,200 or less) increased to 3.64% from 3.52% last week, according to the Mortgage Bankers Association. Refinance applications fell 3% for the week. Applications for a mortgage to purchase a home jumped 8% for the week and set a record for loan size.

 

If you didn’t remember what happen Tuesday night, you won’t be prepared for today’s session:

RegMed Investors’ (RMi) closing bell: “wipe-out. Weak volume, IBB and XBI indexes, Nasdaq trading as traders prepared for the Fed to be more aggressive in tackling unabated inflation and inflation spooks markets” … https://www.regmedinvestors.com/articles/12261   

Ebb and flow – January and Q1 to date:

  • 1 holiday, 1 neutral, 7 negative and 3 positive closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Probabilities versus aftermarket/pre-open share pricing indication moves:

SELL
BioLife Solutions (BLFS) closed down -$1.45 to $29.39 after Friday’s up +$0.24 to $30.84 with a negative -$0.36 or -1.22% pre-open indication.

 

BUY:

bluebird bio (BLUE) closed down -$0.82 to $7.91 after Friday’s +$0.21 to $8.73 and has a positive +$0.08 or +1.01% pre-open indication

Editas Medicine (EDIT) closed down -$2.14 to $19.96 after Friday’s +$0.23 to $22.10, Thursday’s -$1.63 to $21.87 and last Wednesday’s -$2.27 to $23.55, with a positive +$0.05 or +0.25% pre-open indication

CRISPR Therapeutics (CRSP) closed down -$2.72 to $65.06 after Friday’s +$1.37 to $67.77, Thursday’s -$2.85 to $69.86 with a positive +$0.95 or +1.47% pre-open indication,

 

Maintaining SELL:

Biostage (OTCQB: BSTG) closed down -$0.85 to $3.75 after Friday’s flat at $4.60, Thursday’s +$0.63 to $4.60 and last Wednesday’s +$0.77 to $3.97. Is there a reason for the “pump and promote”; are they trying to reverse or convert the non-registered shares from the multiple overpriced private placement (without any valuation models) to register shares beginning a “raise” to protect/satisfy non-U.S. investors?

 

 

The BOTTOM LINE: The stock market suffered another punishing loss Tuesday, easily wiping out Friday's rebound from lows,

Investors should wait for clear-cut evidence of a sustained uptrend. You need to preserve your capital — and your neurotic capacity.

But are there a few safe havens after Tuesday's sell-off and Wednesday’s session?

Could the market bounce on Wednesday? Sure, the market has had plenty of bounces, some lasting a few days, over the past few weeks. But they haven't lasted.

Patience is key. Don't jump the gun, but don't walk away. The oversold usually “pop” after steady declines so, stay “pat”, buying a few decliners or staying in cash.

Sector equities remained under pressure as earnings season is right around the corner.

I am NOT changing my position, “Brace for more choppiness as we move further into the month and the beginning of Q4/21 Q4 and end-of-year numbers”.

  • I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

So, my bottom of the Bottom Line, Investors should be extremely cautious about adding any new exposure.

  • RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.